Use

This test is appropriate only for patients with a previously confirmed diagnosis of B‑cell acute lymphoblastic leukemia (B‑ALL) and is used to monitor minimal residual disease (MRD) with high sensitivity (down to 0.002%), thus providing important prognostic information following therapy including induction or transplant. Immunophenotyping helps establish an immunophenotypic fingerprint of tumor cells to guide monitoring post-therapy or transplant. ([mayocliniclabs.com](https://www.mayocliniclabs.com/test-catalog/overview/608251?utm_source=openai))